Optimizing ALL Treatment
Expert Guidance on Optimizing Treatment Strategies for Acute Lymphoblastic Leukemia

Released: April 16, 2020

Expiration: April 15, 2021

Amir Fathi
Amir Fathi, MD

Activity

Progress
1
Course Completed
B-Cell ALL: New Treatment Directions

Next, we will discuss several immunotherapies for the treatment of B-cell ALL that represent a new era of therapeutics. These include ADCs such as InO, the BiTE blinatumomab, and CAR T‑cell therapies.

Current Immunotherapy Targets in Adult Relapsed/Refractory ALL

InO, an ADC construct, binds to CD22 on the surface of B‑cell lymphoblasts followed by internalization and release of a toxic agent that kills the target tumor cells. Blinatumomab, a BiTE construct, can bind both CD19 on the surface of B‑cell lymphoblasts and CD3 on the surface of T-cells, bringing leukemia cells into proximity with the activated T-cells and causing immunologically mediated cytotoxicity. CAR T-cell therapy consists of genetically modified CD19‑targeted T‑cells that attack CD19‑expressing malignant lymphoid blasts.